US FDA SOP seeks to convey new regulatory expectations to medtech firms faster
This article was originally published in Clinica
Executive Summary
The US FDA is seeking feedback on a procedure that it expects will help its devices unit clarify and communicate to stakeholders more quickly any changes in its regulatory expectations that could affect data submitted as part of a pre-market submission or an investigational device exemption.